Zacks Research Has Negative Outlook of PBH Q3 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Stock analysts at Zacks Research decreased their Q3 2026 earnings estimates for shares of Prestige Consumer Healthcare in a research report issued to clients and investors on Tuesday, September 16th. Zacks Research analyst Team now forecasts that the company will earn $1.21 per share for the quarter, down from their previous estimate of $1.23. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q4 2026 earnings at $1.36 EPS, Q3 2027 earnings at $1.10 EPS and FY2027 earnings at $4.82 EPS.

Other analysts have also recently issued research reports about the stock. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Wall Street Zen cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $93.33.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $63.86 on Wednesday. The firm has a 50 day simple moving average of $69.60 and a 200-day simple moving average of $78.78. Prestige Consumer Healthcare has a 1-year low of $61.93 and a 1-year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The stock has a market cap of $3.14 billion, a price-to-earnings ratio of 14.99, a price-to-earnings-growth ratio of 2.00 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm had revenue of $249.53 million during the quarter, compared to analysts’ expectations of $260.71 million. During the same period last year, the company earned $0.90 EPS. The business’s quarterly revenue was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several large investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its holdings in Prestige Consumer Healthcare by 35.9% during the 1st quarter. GAMMA Investing LLC now owns 1,879 shares of the company’s stock worth $162,000 after buying an additional 496 shares in the last quarter. KBC Group NV lifted its holdings in Prestige Consumer Healthcare by 7.4% during the 1st quarter. KBC Group NV now owns 2,199 shares of the company’s stock worth $189,000 after buying an additional 151 shares in the last quarter. QRG Capital Management Inc. lifted its holdings in Prestige Consumer Healthcare by 8.6% during the 1st quarter. QRG Capital Management Inc. now owns 5,971 shares of the company’s stock worth $513,000 after buying an additional 475 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Prestige Consumer Healthcare by 14.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,315 shares of the company’s stock worth $649,000 after buying an additional 1,030 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in Prestige Consumer Healthcare by 354.0% during the 1st quarter. XTX Topco Ltd now owns 22,778 shares of the company’s stock worth $1,958,000 after buying an additional 17,761 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.